These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29496499)

  • 1. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Tanner NT; Springmeyer SC; Porter A; Jett JR; Mazzone P; Vachani A; Silvestri GA
    Chest; 2021 Mar; 159(3):1283-1287. PubMed ID: 33171158
    [No Abstract]   [Full Text] [Related]  

  • 4. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
    Li XJ; Hayward C; Fong PY; Dominguez M; Hunsucker SW; Lee LW; McLean M; Law S; Butler H; Schirm M; Gingras O; Lamontagne J; Allard R; Chelsky D; Price ND; Lam S; Massion PP; Pass H; Rom WN; Vachani A; Fang KC; Hood L; Kearney P
    Sci Transl Med; 2013 Oct; 5(207):207ra142. PubMed ID: 24132637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.
    Pritchett MA; Sigal B; Bowling MR; Kurman JS; Pitcher T; Springmeyer SC;
    PLoS One; 2023; 18(7):e0287409. PubMed ID: 37432960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated risk predictor for pulmonary nodules.
    Kearney P; Hunsucker SW; Li XJ; Porter A; Springmeyer S; Mazzone P
    PLoS One; 2017; 12(5):e0177635. PubMed ID: 28545097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic characteristics of a serum biomarker in patients with positron emission tomography scans.
    Grogan EL; Deppen S; Pecot CV; Putnam JB; Nesbitt JC; Shyr Y; Rajanbabu R; Ory B; Lambright ES; Massion PP
    Ann Thorac Surg; 2010 Jun; 89(6):1724-8; discussion 1728-9. PubMed ID: 20494018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
    Horeweg N; van Rosmalen J; Heuvelmans MA; van der Aalst CM; Vliegenthart R; Scholten ET; ten Haaf K; Nackaerts K; Lammers JW; Weenink C; Groen HJ; van Ooijen P; de Jong PA; de Bock GH; Mali W; de Koning HJ; Oudkerk M
    Lancet Oncol; 2014 Nov; 15(12):1332-41. PubMed ID: 25282285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation.
    Tanner NT; Porter A; Gould MK; Li XJ; Vachani A; Silvestri GA
    Chest; 2017 Aug; 152(2):263-270. PubMed ID: 28115167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer.
    Vachani A; Whitney DH; Parsons EC; Lenburg M; Ferguson JS; Silvestri GA; Spira A
    Chest; 2016 Jul; 150(1):210-8. PubMed ID: 26896702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules.
    Kheir F; Uribe JP; Cedeno J; Munera G; Patel H; Abdelghani R; Matta A; Benzaquen S; Villalobos R; Majid A
    J Thorac Dis; 2023 Jul; 15(7):3557-3567. PubMed ID: 37559655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.
    Codreanu SG; Hoeksema MD; Slebos RJC; Zimmerman LJ; Rahman SMJ; Li M; Chen SC; Chen H; Eisenberg R; Liebler DC; Massion PP
    J Proteome Res; 2017 Sep; 16(9):3266-3276. PubMed ID: 28731711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.